靶向治疗：谁将受益？ - Suppr

Suppr

超能文献

Targeted therapies: cui prodest?

作者信息

Ferrari Daris, Foa Paolo

出版信息

J Clin Oncol. 2007 Oct 10;25(29):4691-2; author reply 4692. doi: 10.1200/JCO.2007.12.7613.

DOI:10.1200/JCO.2007.12.7613

PMID:17925568

Abstract

摘要

相似文献

Targeted therapies: cui prodest?

J Clin Oncol. 2007 Oct 10;25(29):4691-2; author reply 4692. doi: 10.1200/JCO.2007.12.7613.

Targeted therapy trials: approval strategies, target validation, or helping patients?

J Clin Oncol. 2007 May 1;25(13):1639-41. doi: 10.1200/JCO.2006.09.8384.

Vision and will: the future of the FDA.

Oncologist. 2009 Apr;14(4):317-9. doi: 10.1634/theoncologist.2009-0053. Epub 2009 Apr 13.

Monoclonal antibody successes in the clinic.

Nat Biotechnol. 2005 Sep;23(9):1073-8. doi: 10.1038/nbt0905-1073.

Fast track to MS drug.

Nat Biotechnol. 2004 Aug;22(8):939-41. doi: 10.1038/nbt0804-939.

Clinical update on oncology treatments and trends.

Am J Manag Care. 2006 Mar;12(3 Suppl):S43-70; quiz S71-2.

The fourth modality: immunotherapy for head and neck cancer hits pay dirt.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jun;121(6):575-7. doi: 10.1016/j.oooo.2016.03.019. Epub 2016 Apr 7.

Lessons learned from independent central review.

Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

Phase 0 clinical studies in oncology.

Clin Pharmacol Ther. 2009 Feb;85(2):204-7. doi: 10.1038/clpt.2008.246. Epub 2008 Dec 24.

Where adolescents and young adults with cancer receive their care: does it matter?

J Clin Oncol. 2007 Oct 10;25(29):4522-3. doi: 10.1200/JCO.2007.12.1715.

引用本文的文献

Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors.

Oncotarget. 2019 Apr 23;10(30):2869-2886. doi: 10.18632/oncotarget.26880.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Targeted therapies: cui prodest?

J Clin Oncol. 2007 Oct 10;25(29):4691-2; author reply 4692. doi: 10.1200/JCO.2007.12.7613.

Targeted therapy trials: approval strategies, target validation, or helping patients?

J Clin Oncol. 2007 May 1;25(13):1639-41. doi: 10.1200/JCO.2006.09.8384.

Vision and will: the future of the FDA.

Oncologist. 2009 Apr;14(4):317-9. doi: 10.1634/theoncologist.2009-0053. Epub 2009 Apr 13.

Monoclonal antibody successes in the clinic.

Nat Biotechnol. 2005 Sep;23(9):1073-8. doi: 10.1038/nbt0905-1073.

Fast track to MS drug.

Nat Biotechnol. 2004 Aug;22(8):939-41. doi: 10.1038/nbt0804-939.

Clinical update on oncology treatments and trends.

Am J Manag Care. 2006 Mar;12(3 Suppl):S43-70; quiz S71-2.

The fourth modality: immunotherapy for head and neck cancer hits pay dirt.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jun;121(6):575-7. doi: 10.1016/j.oooo.2016.03.019. Epub 2016 Apr 7.

Lessons learned from independent central review.

Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

Phase 0 clinical studies in oncology.

Clin Pharmacol Ther. 2009 Feb;85(2):204-7. doi: 10.1038/clpt.2008.246. Epub 2008 Dec 24.

Where adolescents and young adults with cancer receive their care: does it matter?

J Clin Oncol. 2007 Oct 10;25(29):4522-3. doi: 10.1200/JCO.2007.12.1715.

引用本文的文献

Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors.

Oncotarget. 2019 Apr 23;10(30):2869-2886. doi: 10.18632/oncotarget.26880.